Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Vaynshteyn K, Deschamps K, Martell M, Jordan HR, Iwamoto M.

J Clin Pharmacol. 2019 Aug;59(8):1093-1098. doi: 10.1002/jcph.1399. Epub 2019 Feb 28.

PMID:
30817001
2.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.

3.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

4.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.

Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, Jordan H, Iwamoto M.

J Clin Pharmacol. 2018 May 3. doi: 10.1002/jcph.1103. [Epub ahead of print]

PMID:
29723418
5.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG.

Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28.

PMID:
29557716
6.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, Triantafyllou I, Hussaini A, Iwamoto M.

Clin Drug Investig. 2017 Oct;37(10):975-984. doi: 10.1007/s40261-017-0552-x.

PMID:
28785879
7.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
8.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, Lai MT, Di Spirito M, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01757-16. doi: 10.1128/AAC.01757-16. Print 2017 Feb.

Supplemental Content

Loading ...
Support Center